Just wanted to add some follow up research from a recent article published by Sepmag at sepmag.eu
There has been a lot of discussion among Anteo investors around the very tightly guarded secrecy surrounding the company known as "POC1" or more recently "Global Healthcare company"
At the Anteo AGM the "POC1" company was discussed and the reason the company hasn't allowed Anteo to announce who "POC1" is because of a company protocol which requires Anteo not to announce them formally until 12 months before product launch.
If speculation proves correct that "POC1" is indeed Philips Healthcare then a scheduled product launch for the Philips Minicare device late 2015 means Anteo may be very close to offically being able to announce their partnership with Philips and what it involves.
I suggest readers have a look at the article below written by Anteo VP Scientific Affairs Joshua Soldo :
The article can be found on pages 9 & 10
Surface Attenuation for High Sensitivity Assays
Below are some interesting points for discussion from this article :
Since conventional solid phase chemistry approaches to bind ligands may not result in a desired “highsensitivity”binding surface due to steric hindrance
(surface crowding),misorientation,and/or ligand inactivation (no longer in a native or active orientation),there has been a need for new conjugation
processes that maximize ligand functionality and actual binding capacity
Photos above not from Sepmag article taken from :
More recently, the group of Philips Research (High Tech Campus, 5656 AE Eindhoven, The Netherlands) published an article that further demonstrates the importance of antibody-capturing activity of antibody-coated nanoparticles
However, in this study the antibodies were non directionally immobilized on a nanoparticle surface,and they were not able to fully realize the optimal immunoassay response if the antibodies would have been both non-saturated and orientated.
While classical approaches to ligand conjugation often result in non-optimized binding surfaces due to crowding, conformational change, and/or poor orientation, there are new approaches available today to support the development of ultra sensitive assays such titrating the amount of ligand per unit surface area instead of using molar excess, or metal polymer chemistry by Anteo Technologies. With these new approaches scientists
should be able to more readily and efficiently develop
the next generation of immunoassays using their
test system and surface(s) of choice.